Abstract
The presence of estramustine-binding protein has been suggested to positively correlate with the effect of the cytotoxic drug estramustine, a combination of estradiol and nornitrogen mustard used in the treatment of prostatic carcinoma. This study demonstrates expression of estramustine-binding protein in a series of meningioma using different ligand-based and immunological techniques. Scatchard plot analysis showed specific binding sites for [3H]estramustine in meningioma tissue with a dissociation constant of 22–26 nM. Immunohistochemistry revealed an immunoreactivity in meningioma comparable to that demonstrated in prostatic carcinoma. The mean concentration (n = 6) of estramustine-binding protein in meningioma, as determined by radioimmunoassay was 159 ng/g tissue (range 18–274 ng/g). Moreover, partial characterization using size exclusion chromatography of [3H]estramustine-labeled tumor extracts and Western blot analysis of immunoprecipitated samples indicated that the structure of the estramustine-binding protein in meningioma is similar to that in rat prostate, with three polypeptide components of 10, 14, and 16 kDa, as compared to 8, 10–11, and 12 kDa in rat prostate. In conclusion, the novel observation of estramustine-binding protein and specific binding of estramustine in meningioma justify further evaluation regarding the role of estramustine-binding protein in the growth behavior of meningioma and the potential for estramustine and similar hormone-related drugs in the treatment of relapsing meningioma.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 30 September 1998 / Revised, accepted: 21 December 1998
Rights and permissions
About this article
Cite this article
Karlsson, A., Bergenheim, A., Björk, P. et al. Estramustine-binding protein in meningioma. Acta Neuropathol 98, 135–140 (1999). https://doi.org/10.1007/s004010051061
Issue Date:
DOI: https://doi.org/10.1007/s004010051061